These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 38666475)

  • 41. Clinical study of lamotrigine and valproic acid in patients with epilepsy: using a drug interaction to advantage?
    Morris RG; Black AB; Lam E; Westley IS
    Ther Drug Monit; 2000 Dec; 22(6):656-60. PubMed ID: 11128232
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Population pharmacokinetics of oxcarbazepine active metabolite in Chinese children with epilepsy.
    Peng J; Zhang HN; Liu ZS; Xu H; Wang Y
    Int J Clin Pharmacol Ther; 2014 Aug; 52(8):684-92. PubMed ID: 24887335
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Population pharmacokinetic modeling of oxcarbazepine active metabolite in Chinese patients with epilepsy.
    Yu Y; Zhang Q; Xu W; Lv C; Hao G
    Eur J Drug Metab Pharmacokinet; 2016 Aug; 41(4):345-51. PubMed ID: 25700977
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacogenetics-based population pharmacokinetic analysis and dose optimization of valproic acid in Chinese southern children with epilepsy: Effect of
    Shen X; Chen X; Lu J; Chen Q; Li W; Zhu J; He Y; Guo H; Xu C; Fan X
    Front Pharmacol; 2022; 13():1037239. PubMed ID: 36506519
    [No Abstract]   [Full Text] [Related]  

  • 45. Effects of UGT1A4 genetic polymorphisms on serum lamotrigine concentrations in Chinese children with epilepsy.
    Wang Q; Liang M; Dong Y; Yun W; Qiu F; Zhao L; Guo Y
    Drug Metab Pharmacokinet; 2015 Jun; 30(3):209-13. PubMed ID: 25922177
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Estimation and comparison of carbamazepine population pharmacokinetics using dried blood spot and plasma concentrations from people with epilepsy: the clinical implication.
    Kong ST; Lim SH; Chan E; Ho PC
    J Clin Pharmacol; 2014 Feb; 54(2):225-33. PubMed ID: 23996245
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Joint use of population pharmacokinetics and machine learning for prediction of valproic acid plasma concentration in elderly epileptic patients.
    Ma P; Shang S; Huang Y; Liu R; Yu H; Zhou F; Yu M; Xiao Q; Zhang Y; Ding Q; Nie Y; Wang Z; Chen Y; Yu A; Shi Q
    Eur J Pharm Sci; 2024 Oct; 201():106876. PubMed ID: 39128815
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Influence of the UGT2B7 -161C>T polymorphism on the population pharmacokinetics of lamotrigine in Thai patients.
    Singkham N; Towanabut S; Lertkachatarn S; Punyawudho B
    Eur J Clin Pharmacol; 2013 Jun; 69(6):1285-91. PubMed ID: 23263737
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Influence of concomitant antiepileptic drugs on plasma lamotrigine concentration in adult Japanese epilepsy patients.
    Yamamoto Y; Inoue Y; Matsuda K; Takahashi Y; Kagawa Y
    Biol Pharm Bull; 2012; 35(4):487-93. PubMed ID: 22466551
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An investigation of the influence of patient-related factors and comedications on lamotrigine clearance in patients with epilepsy.
    Baldoni AO; Freitas-Lima P; de Santi Ferreira FI; Martinez EZ; Queiroz RH; Sakamoto AC; Alexandre V; Perucca E; Pereira LR
    Clin Exp Pharmacol Physiol; 2016 Jul; 43(7):685-9. PubMed ID: 27120710
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Population Pharmacokinetics Modeling of Lamotrigine in Jordanian Epileptic Patients Using Dried Blood Spot Sampling.
    Dodin YI; Suyagh MF; Saleh MI; Nuseir ZT; Aburuz SM; Al-Qudah AA; Masri AT; Younes AM; Al-Ghazawi MA
    Drug Res (Stuttg); 2021 Oct; 71(8):429-437. PubMed ID: 34255318
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Lamotrigine pharmacokinetics following oral and stable-labeled intravenous administration in young and elderly adult epilepsy patients: Effect of age.
    Polepally AR; Brundage RC; Remmel RP; Leppik IE; Pennell PB; White JR; Ramsay RE; Kistner BM; Birnbaum AK
    Epilepsia; 2018 Sep; 59(9):1718-1726. PubMed ID: 30101556
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Predictability of individualized dosage regimens of carbamazepine and valproate mono- and combination therapy.
    Bondareva IB; Jelliffe RW; Andreeva OV; Bondareva KI
    J Clin Pharm Ther; 2011 Oct; 36(5):625-36. PubMed ID: 21062333
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy.
    Wang Y; Zhang HN; Niu CH; Gao P; Chen YJ; Peng J; Liu MC; Xu H
    Acta Pharmacol Sin; 2014 Oct; 35(10):1342-50. PubMed ID: 25220641
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacokinetic modeling of valproate from clinical data in Serbian epileptic patients.
    Jankovic SM; Milovanovic JR
    Methods Find Exp Clin Pharmacol; 2007 Dec; 29(10):673-9. PubMed ID: 18200330
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Population Pharmacokinetics of Valproic Acid in Patients with Mania: Implication for Individualized Dosing Regimens.
    Methaneethorn J
    Clin Ther; 2017 Jun; 39(6):1171-1181. PubMed ID: 28483293
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation of VPA dose and concentration effects on lamotrigine pharmacokinetics: implications for conversion to lamotrigine monotherapy.
    Gidal BE; Sheth R; Parnell J; Maloney K; Sale M
    Epilepsy Res; 2003 Dec; 57(2-3):85-93. PubMed ID: 15013050
    [TBL] [Abstract][Full Text] [Related]  

  • 58. How to replace lamotrigine with valproate.
    Steinhoff BJ
    Epilepsia; 2006 Nov; 47(11):1943-4. PubMed ID: 17116036
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Simultaneous determination of plasma lamotrigine, lamotrigine N2-glucuronide and lamotrigine N2-oxide by UHPLC-MS/MS in epileptic patients.
    Yang H; Zhang D; Mei S; Zhao Z
    J Pharm Biomed Anal; 2022 Oct; 220():115017. PubMed ID: 36030754
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Population pharmacokinetics of valproic acid in pediatric patients with epilepsy: considerations for dosing spinal muscular atrophy patients.
    Williams JH; Jayaraman B; Swoboda KJ; Barrett JS
    J Clin Pharmacol; 2012 Nov; 52(11):1676-88. PubMed ID: 22167565
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.